15.76
+2.43(+18.23%)
Currency In NaN
| Previous Close | 13.33 |
| Open | 13.5 |
| Day High | 15.87 |
| Day Low | 12.51 |
| 52-Week High | 19.58 |
| 52-Week Low | 4.88 |
| Volume | 169,641 |
| Average Volume | 77,909 |
| Market Cap | 341.93M |
| PE | -12.31 |
| EPS | -1.28 |
| Moving Average 50 Days | 10.36 |
| Moving Average 200 Days | 10.47 |
| Change | 2.43 |
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
GlobeNewswire Inc.
May 19, 2025 8:10 PM GMT
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SAN DIEGO, Ma
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
GlobeNewswire Inc.
May 07, 2025 8:05 PM GMT
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the t